Effect of tibolone on the survival of early stage cervical adenocarcinoma patients

Gynecologic oncologists are uncertain about the safety of tibolone application in cervical adenocarcinoma (AC) patients. This study examined the possible adverse effects of tibolone on the survival of cervical AC patients. Medical records of 70 cervical AC patients with International Federation of G...

Full description

Saved in:
Bibliographic Details
Published in:Obstetrics & gynecology science 2018, 61(5), 641, pp.584-589
Main Authors: Lee, Seung-Ho, Cho, Yoon-Jin, Cho, Kyung-Joo, Ko, Mee-Hyang, Jung, Sun-Young, Chon, Seung-Joo, Lim, So-Yi, Lee, Kwang-Beom
Format: Article
Language:English
Subjects:
adenocarcinoma
Original
prognosis
survival
tibolone
uterine cervical neoplasm
산부인과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gynecologic oncologists are uncertain about the safety of tibolone application in cervical adenocarcinoma (AC) patients. This study examined the possible adverse effects of tibolone on the survival of cervical AC patients. Medical records of 70 cervical AC patients with International Federation of Gynecology and Obstetrics stages IA to IB were reviewed. A bilateral salpingo-oophorectomy was performed in all patients, and survival outcomes between tibolone users (n=38) and non-users (n=32) were compared. A comparison of the tibolone users with non-users revealed similar clinicopathological variables. Progression-free survival ( =0.34) and overall survival ( =0.22) were similar in the users and non-users. The risks of progression (hazard ratio [HR], 1.71; 95% confidence interval [CI], 0.46-6.37; =0.43) and death (HR, 1.59; 95% CI, 0.06-45.66; =0.79) were also similar in both groups. Tibolone has no adverse effect on the survival of cervical AC patients and can be administered safely to this population. These findings may be helpful in improving the quality of life of cervical AC patients.
ISSN:2287-8572
2287-8580
DOI:10.5468/ogs.2018.61.5.584